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Abstract

Author Manuscript

Objective: To evaluate associations between executive functioning and caregiver adherence
monitoring with objective antihypertensive medication adherence over 24 months in adolescents
with chronic kidney disease (CKD).
Methods: Adolescents (N = 97, 11–20 years old) with CKD taking antihypertensive medication
and their caregivers were recruited from three pediatric nephrology clinics. At baseline,
adolescents and caregivers reported on adolescents’ executive functioning and caregivers reported
on their adherence monitoring. Antihypertensive medication adherence was objectively assessed
via electronic monitoring at baseline and every 6 months after for 24 months. Associations
between executive functioning, caregiver monitoring, and longitudinal adherence were evaluated
with linear mixed models.

Author Manuscript

Results: Up to 38% of adolescents had elevated executive functioning scores indicating more
severe impairments, with rates varying by scale and reporter (adolescent versus caregiver).
Caregiver monitoring showed a significant, negative association with adherence, but adolescents’
executive functioning was not significantly associated with adherence. Neither variable was
associated with the rate of change in adherence over time.
Conclusions: Given that adolescents’ executive functioning was not associated with
antihypertensive medication adherence or changes in adherence over time, adherence to daily pillform medications may involve less cognitive effort than more complex medical regimens. Higher
levels of caregiver monitoring were unexpectedly associated with lower adherence levels. This
unanticipated finding may reflect increased caregiver monitoring efforts when faced with
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adolescents’ medication nonadherence, but this finding warrants further investigation. Adolescents
with CKD who are nonadherent may benefit from medication adherence-promoting strategies
beyond increasing caregiver monitoring.
Keywords
adherence; executive functioning; caregiver monitoring; kidney diseases

Author Manuscript

Hypertension and proteinuria are major risk factors for chronic kidney disease (CKD)
progression in children (Fathallah-Shaykh, 2017; Wühl & Schaefer, 2008). Lowering blood
pressure and decreasing urinary protein excretion with antihypertensive medications are
renal protective strategies that reduce the risk for disease progression and the development
of end stage renal disease (ESRD; Wühl & Schaefer, 2008; Wühl et al., 2009). Among
children with CKD, adherence to antihypertensive medications is suboptimal, with onequarter to one-third not regularly taking their prescribed medication, depending on
adherence assessment method (electronic monitoring of medication self-administration or
pharmacy refill adherence, respectively; Pruette et al., 2019). Inconsistent antihypertensive
medication adherence may contribute to accelerated CKD progression in youth.

Author Manuscript

Executive functioning, which includes the subdomains of behavior regulation (ability to shift
one’s mindset and use emotional control to meet one’s goals) and metacognition (ability to
monitor, plan, organize, and sustain future-oriented problem solving; Gioia, Isquith, Guy, &
Kenworthy, 2000), is associated with medication adherence in children with other chronic
illnesses. In adolescents with solid organ transplants, including kidney, approximately 25%
had clinically significant levels of broad executive function impairment, and more severe
caregiver proxy-reported impairments in metacognition were cross-sectionally associated
with higher levels of adolescent-reported medication nonadherence (Gutiérrez-Colina et al.,
2016). Similarly, in children and adolescents with type 1 diabetes (T1D), caregiver proxyreported impairments in behavior regulation were associated with decreased adolescentreported self-management skills over 2 years (Miller et al., 2012). Further, as youth with
T1D emerge into adulthood, better broad executive functioning abilities have been
associated with less rapid increases in blood glucose levels over 2 years (reflecting better
disease management), even after controlling for intellectual functioning (Berg et al., 2018).

Author Manuscript

Despite evidence of these associations in adolescents with T1D or transplants, little work has
examined the influence of executive function impairments on adherence in youth with CKD.
Children and adolescents with CKD generally exhibit lower executive functioning abilities,
particularly within metacognition (scoring approximately .5–1 standard deviations higher in
an index of metacognitive impairment than the general population; Chen et al., 2018). Up to
40% of children in the Chronic Kidney Disease in Childhood (CKiD) cohort study had
parent-reported and objectively-assessed executive functioning levels ≥1 standard deviation
(SD) below the mean of an age-adjusted normal population (Hooper et al., 2011; Mendley et
al., 2015). Further, increased blood pressure variability, a risk factor for renal function
decline and ESRD (Sethna et al., 2017), was associated with higher levels of executive
functioning impairments in children and adolescents with CKD (Lande et al., 2016). These
findings suggest that adolescents with CKD may have higher incidence of executive

Health Psychol. Author manuscript; available in PMC 2021 August 06.

Eaton et al.

Page 3

Author Manuscript

functioning impairments compared to the general population, which likely confers greater
risk for medication nonadherence and disease progression over time. However, these
associations have yet to be empirically evaluated.

Author Manuscript

Caregiver monitoring, which includes a caregiver’s awareness of their child’s location,
behaviors, goals, and activities and involvement in helping their child reach his/her goals
(Stattin & Kerr, 2000), may also be related to children’s adherence. Higher levels of
caregiver monitoring have been associated cross-sectionally and longitudinally with better
glycemic control in youth with T1D (Berg et al., 2017; Ellis et al., 2007; Robinson et al.,
2016), suggesting that caregiver monitoring may facilitate completion of appropriate disease
self-management behaviors. Among adolescents with epilepsy, higher levels of caregiver
involvement in managing antiepileptic drugs (AEDs) were associated with higher AED
adherence over time (Holbein, Smith, Peugh, & Modi, 2019) but caregiver involvement in
their children’s daily lives in general was not (Smith, Mara, & Modi, 2018). Similarly,
among adolescents and young adults with T1D, individuals with higher levels of executive
functioning impairments demonstrated lower (better) blood glucose levels when caregiver
involvement in diabetes care was higher (Berg et al., 2019). Hence, caregiver monitoring of
medical management tasks may offset negative contributions of executive functioning
impairments on adolescents’ adherence.

Author Manuscript

The interplay of caregiver factors (including caregiver monitoring of medical regimens) and
child cognitive processes and associated behavior processes (including executive
functioning) are theorized as being critical in predicting adherence outcomes in youth with
chronic medical conditions (Lansing & Berg, 2014), suggesting similar associations will be
observed among adolescents with CKD. However, associations of adolescent executive
functioning and caregiver monitoring with adherence have predominately been examined in
the T1D literature or relied on self-reported adherence. Hence, this study used linear mixed
models to examine associations of executive functioning and caregiver monitoring of
medication adherence with objectively- and longitudinally-assessed antihypertensive
medication adherence in adolescents with CKD. We hypothesized that higher levels of
adolescents’ executive functioning impairments (baseline) and lower levels of caregiver
monitoring (baseline) would be associated with lower antihypertensive medication
adherence measured over 24 months (between-person effects).

Methods
Procedures

Author Manuscript

Recruitment occurred at three pediatric nephrology clinics in the mid-Atlantic United States.
Each site’s Institutional Review Board (Johns Hopkins School of Medicine, University of
Maryland School of Medicine, Children’s National Health System) approved study
procedures. Adolescents (ages 11–19 years at informed consent) with a physician-verified
diagnosis of CKD (stages 1–5) and current prescription for an antihypertensive medication
were included. Adolescents who had a sibling participating in the study, were unable to
understand spoken English, had a developmental delay or significant cognitive impairment
that would preclude their ability to complete study procedures (as reported by their pediatric
nephrologist or primary caregiver), or declined to use electronic medication monitoring
Health Psychol. Author manuscript; available in PMC 2021 August 06.
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devices during study participation were excluded. Caregivers of eligible adolescents <18
years old were invited to participate; caregivers of eligible adolescents ≥18 years old were
invited to participate if they actively participated in adolescents’ medical care. By reviewing
clinic rosters and electronic medical records, trained research assistants (RAs) identified
adolescents who appeared to meet eligibility criteria. Potentially eligible adolescents were
mailed a letter describing the study and providing the opportunity to opt out of recruitment.
Individuals who did not opt out of study recruitment were contacted via telephone and
invited to join the study. For adolescents and caregivers who agreed to participate, written
informed consent and assent were completed at the first study visit, which occurred at
adolescents’ homes or a family-preferred location.

Author Manuscript

Adolescents and caregivers completed surveys (detailed below) at baseline administered
with audio-enhanced computer-assisted self-interviewing (audio CASI). Given the interrelation between executive functioning and intellectual functioning, we assessed
adolescents’ general cognitive abilities with an intellectual functioning screener (WASI-II) at
baseline. Antihypertensive medication adherence was measured continuously via electronic
monitoring for two weeks at baseline and 6-, 12-, 18-, and 24-months after baseline.
Families received $100 for completing full assessments at baseline, 12- and 24-months and
$50 for completing shorter assessments at 6- and 18-months after baseline.
Surveys

Author Manuscript

Demographic and medical information.—Adolescents ≥18 years old and caregivers of
adolescents <18 years old reported demographic information (e.g., race, family income) at
baseline. Electronic medical record (EMR) review identified those with co-morbid
hypertension diagnoses and allowed for calculating estimated glomerular filtration rate
(eGFR) to determine CKD disease stage ((0.413*height/creatinine; Schwartz et al., 2009).

Author Manuscript

Executive functioning.—The 80-item Behavior Rating Inventory of Executive FunctionSelf-Report (BRIEF-SR; Guy, Gioia, & Isquith, 2004) and the 86-item Behavior Rating
Inventory of Executive Function-Parent Form (BRIEF-P; Gioia et al., 2000) evaluated
adolescents’ executive functioning abilities at baseline. Adolescents and caregivers rated
how much an item was problematic in the last 6 months using a 3-point Likert scale ranging
from Never to Often (e.g., “I don’t plan ahead for future activities”; “[My child] Has a short
attention span”). The BRIEF-SR and BRIEF-P contain 8 scales comprising the Behavioral
Regulation Index (BRI; i.e., ability to exert inhibitory control over one’s behaviors and
emotions) and the Metacognition Index (MCI; i.e., ability to initiate, plan, organize, selfmonitor, and sustain working memory). The BRI and MCI comprise the Global Executive
Composite (GEC) score reflecting overall executive functioning impairments. Raw scores
were converted to age- and gender-normed T-scores. For adolescents ≥19 years at baseline (n
= 8), the highest available age and gender norms were used to determine T-scores. Higher
scores indicate more severe executive functioning impairments. The majority of responses
were Acceptable on the Negativity scale (99% on the BRIEF-SR and -P) and the
Inconsistency scale (97% on the BRIEF-SR and -P). In this study, α = .95 on the BRIEF-SR
and α = .98 on the BRIEF–P.

Health Psychol. Author manuscript; available in PMC 2021 August 06.
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Caregiver monitoring of adolescents’ adherence to antihypertensive medications was
assessed via caregivers’ responses to three items modified from the Parental Monitoring of
Diabetes Care scale (Ellis et al., 2007). Items were modified to evaluate taking
antihypertensive medications rather than performing diabetes care tasks. The following three
items were selected for face validity in evaluating the extent to which caregivers monitored
how their adolescent took their medicine: “How often did you watch your child take his/her
antihypertensive medication?” “How often did you ask your child if he/she took his/her
antihypertensive medication?” and “How often do you have to remind your child to take
his/her antihypertensive medication?” Each item was rated on a 5-point Likert scale ranging
from Never (0) to Every time (4). Item ratings were summed to create a total score with
higher scores indicating higher levels of caregiver monitoring. Regarding internal
consistency, α = .62 in the current sample.
General Cognitive Abilities
The Vocabulary and Matrix Reasoning subtests of the Wechsler Abbreviated Scale of
Intelligence Second Edition (WASI-II; Wechsler, 2011) were used as a general cognitive
abilities screener at baseline. Subtests were administered as part of this study by trained RAs
who were supervised by licensed clinical psychologists on the study team. Raw scores were
converted to age-normed T-scores to determine adolescents’ general cognitive abilities with
the Full Scale Intellectual Quotient-2 Subtests (FSIQ-2).
Objective Antihypertensive Medication Adherence

Author Manuscript

Medication Event Monitoring System (MEMS 6) TrackCap monitors (AARDEX Ltd. Union
City, CA) assessed daily antihypertensive medication administration. The MEMS cap
records the time and date of each bottle opening and closure. Before each study visit, the RA
obtained adolescents’ antihypertensive medication regimens (EMR and physician
confirmed) including the names of their antihypertensive medication(s), dosages, and
schedules. The RA placed the medication in the MEMS bottle. If more than one
antihypertensive medication was prescribed, each medication was monitored with a separate
MEMS cap and bottle. Adherence was calculated as the number of MEMs cap openings /
the total number of expected openings based on the prescribed regimen and the number of
days observed. If multiple medications were monitored, average adherence was calculated
for each individual medication and then averaged across medications to create a single
composite adherence score. The intraclass correlation indicated that 44% of the variance in
adherence measurements was between-persons.

Author Manuscript

Analysis Plan
Descriptive statistics (e.g., mean, SD, range) were calculated for primary study variables.
Proportions of adolescents in the Clinically Significant (T-score ≥65), At-risk (T-score ≥60),
and Sub-clinical ranges (T-score <60) for the BRIEF-SR and –P scales were calculated.
Linear mixed models (PROC MIXED; SAS 9.4 Software, Cary, NC) were used to evaluate
associations between baseline executive functioning and baseline caregiver monitoring in
predicting level of adherence as well as the rate of change in adherence over 24 months. An
Health Psychol. Author manuscript; available in PMC 2021 August 06.
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alpha level of p<.05 was used to test statistical significance. The restricted maximum
likelihood estimation and autoregressive covariance structure were used to allow for some
missingness in the data and to account for expected correlations between repeated measures
within individuals over time. There was 2% missingness in caregiver proxy-reported survey
scale scores, 3% missingness in adolescent-reported survey scale scores, and 16%
missingness across all five MEMS cap measurement time points. The fully observed dataset
was analyzed. Sensitivity analyses assessed potential patterns of missingness in adherence
data based on whether adolescents’ antihypertensive medications were discontinued by their
prescribing nephrologist after baseline (n = 13). Associations between key study variables
were similar when adolescents with discontinued medications were excluded. Hence,
adolescents whose medications were discontinued during the study were included in final
analyses to enhance generalizability. Given that the BRIEF-SR and -P were administered to
adolescents ≥19 years old and their caregivers at baseline, we also conducted sensitivity
analyses to assess the pattern of effects when these individuals were excluded. The pattern of
effects were similar when adolescents ≥19 years old and their caregivers were excluded and,
therefore, these individuals were included in final analyses.

Author Manuscript

Preliminary analyses to evaluate change in adherence over time informed whether time was
modeled as a linear or quadratic effect with a subject-level random intercept and random
slope. Akaike Information Criterion (AIC) values were used to select the best fitting model
(if the difference in AIC values were ≤2, the more parsimonious random intercept fixed
slope model was selected; Hilbe, 2011).

Author Manuscript

To evaluate associations of baseline executive functioning (grand mean centered) and
baseline caregiver monitoring (grand mean centered) with adherence over time, BRIEF-SR
BRI, MCI, and GEC scales (T-scores) were entered in three separate models with caregiver
monitoring (sum scores) and an interaction term between the predictors and time. The same
analytic approach was used to evaluate whether the BRIEF-P scales (T-scores) and caregiver
monitoring (sum scores) predicted adherence over time. The following covariates (baseline)
were included in each model: adolescent age, gender (1 = female, 0 = male), race (1 =
Caucasian, 0 = non-Caucasian), FSIQ-2, regimen complexity (number of antihypertensive
medications prescribed [1 = one medication prescribed, 0 = >1 medication prescribed],
prescribed number of daily antihypertensive medication doses [1 = one daily dose, 0 = >1
daily dose]), and disease characteristics (transplant status [1 = transplant, 0 = no transplant],
ESRD status [1 = ESRD, 0 = no ESRD]). Consistent with prior research investigating
executive functioning and adherence, the FSIQ-2 was included as a covariate to account for
potential contributions of cognitive abilities to executive functioning (Wiebe et al., 2018).
All other covariates were based on factors commonly associated with pediatric adherence
(Hommel, Ramsey, Rich, & Ryan, 2017).

Author Manuscript

Results
Participants
A total of 130 adolescents with CKD enrolled in this study; two adolescents were excluded
after enrollment due to extremely low FSIQ-2 scores on the WASI-II from which it was
determined that study participation would not be appropriate (would preclude completion of
Health Psychol. Author manuscript; available in PMC 2021 August 06.
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surveys), resulting in 128 adolescent participants. There were no differences in age, gender,
or race between those who participated and those who declined to participate (N = 134). Of
those who declined to participate, 10 stated an unwillingness to use the MEMS cap to
electronically monitor antihypertensive medication adherence as their reason for not
enrolling.

Author Manuscript

Of the 128 who participated, 97 adolescents (M age = 14.87 years, SD = 2.32, Range = 11 to
20) completed adherence monitoring and surveys at baseline and had a caregiver
participating in the study who completed proxy-reported executive functioning and caregiver
monitoring surveys at baseline (N = 97; Figure 1). Only 3 participants refused to continue in
the study over the course of data collection. The majority of adolescents (n = 58) completed
adherence monitoring on all 5 assessment opportunities. The average number of adherence
assessments was 4.22 (SD = 1.16). The most frequent reason for missing MEMS data was
provider discontinuation of antihypertensive medication prescription (6 months n = 6; 12
months n = 6; 18 months n = 9; 24 months n = 12). There were no demographic differences
between adolescents with all 5 adherence assessments versus adolescents missing ≥1
adherence assessments.
The majority of the final sample were male, African American (n = 40) or Caucasian (n =
41), and had private health insurance. Most adolescents took one antihypertensive
medication at baseline and less than half had a hypertension diagnosis (Table 1). The sample
was diverse in terms of CKD stage and family income. The majority of caregivers were
female (72%; n = 70) and the adolescent’s biological parent (99%; n = 96).
Descriptive Data on Primary Study Variables

Author Manuscript

Descriptive statistics for adherence, executive functioning, and caregiver monitoring appear
in Table 2. The prevalence of adolescents in the Clinically Significant (T-score ≥65), At-risk
(T-score ≥60), and Sub-clinical ranges (T-score <60) of the BRIEF-SR and -P appear in
Table 3. Adolescent responses to the BRIEF-SR indicated 8–11% fell in the Clinically
Significant range and 18–22% fell in the At-risk range for problems with executive
functioning. Caregiver responses to the BRIEF-P indicated 18–24% of adolescents fell in the
Clinically Significant range and 27–38% fell in the At-risk range for problems with
executive functioning.
Preliminary Analyses to Assess Changes in Adherence Over Time

Author Manuscript

Adherence decreased linearly over time (β = −2.71, SE = .77, t = −3.53, p < .001); there was
a significant random intercept for subject (variance estimate = 291.51, p < .001) but not a
random slope (variance estimate = 4.30, p = .28). There was no quadratic effect of time (β =
−1.02, SE = .59, t = −1.73, p = .08). Based on the AIC, the linear random intercept fixed
slope model (AIC = 3730.3) was selected over the linear random intercept and random slope
model (AIC = 3732.0).

Health Psychol. Author manuscript; available in PMC 2021 August 06.
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Are Executive Functioning and Caregiver Monitoring Associated with Adherence Over
Time?
In the linear mixed models (Table 4) analyzing associations between baseline adolescentreported executive functioning and adherence over time, there were no significant main
effects for the BRIEF-SR BRI, MCI, or GEC scales. Baseline caregiver monitoring was
negatively associated with adherence in each model (βs = −2.80 to −2.87, ps = .03). None of
the Time × predictor interactions in any of the models were statistically significant.
In the caregiver proxy-reported executive functioning linear mixed models (Table 4), there
were no significant main effects for the baseline BRIEF-P BRI, MCI, or GEC scales.
Baseline caregiver monitoring was negatively associated with adherence in the model
including the BRI (β = −2.73, p = .04) but not the MCI or GEC. None of the Time ×
predictor interactions were statistically significant.

Author Manuscript

Post-Hoc Analyses
Due to unexpected negative associations between caregiver monitoring and adherence, we
conducted post-hoc analyses to further evaluate this association. First, we conducted a linear
mixed model excluding the BRIEF-SR or –P subscales. In this model, caregiver monitoring
continued to show a significant negative association with adherence (β = −2.93, p = .02).

Author Manuscript

Due to lower internal consistency for the caregiver monitoring scale, we evaluated our
models with caregiver monitoring as a binary cutpoint score rather than a sum score. We
calculated the binary variable as 1 = caregiver rated ≥1 item as 3 (Most times) or 4 (Every
time) and 0 = caregiver rated all three items ≤2 (Sometimes or less frequently). When this
variable was included in the models, caregiver monitoring showed a negative association
with adherence which did not reach statistical significance for the models including the
BRIEF-SR (βs = −6.49–−8.07, ps = .30–.24) or the BRIEF-P (βs = −2.87–−6.05, ps
= .38–.69).
We also calculated the binary caregiver monitoring variable as 1 = caregiver rated ≥1 item as
4 (Every time) and 0 = caregiver rated all three items as ≤3 (Most times or less frequently).
When this variable was included in the models, the same negative, non-statistically
significant association with adherence was found in the models including the BRIEF-SR (βs
= −5.16–−5.26, ps = .36–.38) or the BRIEF-P (βs = −2.92–−4.31, ps = .45–.61).

Discussion
Author Manuscript

This study examined associations of baseline self- and caregiver proxy-report measures of
executive functioning (BRIEF-SR and -P) and caregiver monitoring with electronicallymonitored antihypertensive medication adherence over a 24 month period of time in
adolescents with CKD. Contrary to hypotheses, lower adherence was significantly
associated with higher levels of caregiver monitoring sum scores in all but two of the linear
mixed models (the opposite direction than expected) and was not significantly associated
with executive functioning. Neither caregiver monitoring nor executive functioning were
associated with the rate of change in adherence over time. However, when caregiver
monitoring was examined in the models as a cutpoint score in post-hoc analyses, none of the

Health Psychol. Author manuscript; available in PMC 2021 August 06.
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associations with adherence remained statistically significant. These unexpected findings
may reflect our community-based sample of adolescents with CKD who did not have
significant cognitive delays and for whom the majority did not present with significantly
impaired executive functioning. The findings may suggest that caregivers monitor
medication adherence more in response to adolescents not consistently taking their
antihypertensive medicine. However, the unexpected findings and potential psychometric
limitations of the caregiver monitoring scale indicate that further investigation of these
associations is warranted.

Author Manuscript

A meta-analysis and systematic review showed that children and adolescents with CKD may
have more severe executive functioning impairments (i.e., scoring 3.50–5.90 points higher
on BRIEF indexes compared to the general population; Chen et al., 2018). Our sample’s
levels of executive functioning impairment were more variable and largely dependent on the
rater. Adolescents rated themselves only 1.45 to 2.44 points above the mean on BRIEF
indexes, with 8–11% of adolescents endorsing clinically significant impairments. In contrast,
caregivers rated adolescents from 4.20 to 7.33 points above the mean on BRIEF-P indexes
(greatest impairments noted in metacognition), with 18–24% endorsing clinically significant
impairments. The differences in BRIEF-SR and –P rates are consistent with the tendency for
adolescents to report fewer impairments than caregiver proxy-reports (Cassidy et al., 2015).
Our sample’s BRIEF-P ratings are similar to those reported in prior literature (Chen et al.,
2018). The proportion of our sample that had BRIEF-SR and -P scores in the At-risk range
of impairment (SD ≥ 1; 18%–38%) are also comparable to the BRIEF-P scores in the CKiD
cohort (Hooper et al., 2011).

Author Manuscript

The lack of association between executive function domains and time interactions with
adherence contrasts with prior longitudinal and cross-sectional findings from samples of
adolescents and young adults with T1D (Miller et al., 2012) and solid organ transplant
(Gutierrez-Colina et al., 2016). Average BRIEF-SR and -P scores were similar between the
current sample and those reported in prior investigations of executive functioning and selfreported adherence or glycemic control (Berg et al., 2018; Gutierrez-Colina et al., 2016;
Miller et al., 2012). Our study exclusively measured adherence to antihypertensive
medications via electronic monitoring and most adolescents only took one antihypertensive
medication per day. Taking one daily medication that does not require precise dosage timing
may involve fewer executive functions than more complex regimens (e.g., self-managing
T1D or following specifically timed immunosuppressive medication regimens).
Alternatively, the lack of associations we describe may be due to small sample size and
lower incidence of executive functioning impairments limiting power to detect significant
effects.

Author Manuscript

Contrary to hypotheses, higher levels of caregiver monitoring sum scores were associated
with significantly lower antihypertensive medication adherence in models including the
BRIEF-SR and the model including the BRIEF-P BRI scale. There were no time by
predictor interactions. Given psychometric limitations of the caregiver monitoring tool, we
further investigated the unexpected results using binary cutpoint scores. In these post-hoc
analyses, the directionality of the associations continued to be negative but were no longer
statistically significant. The current findings diverge from those reported in youth with T1D
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in which higher levels of caregiver monitoring were associated with higher self-reported
adherence (Berg et al., 2017; Ellis et al., 2007; Robinson et al., 2016). T1D involves selfmanaging a range of domains (e.g., blood glucose monitoring, insulin administration,
medication adherence, meal planning), which may benefit from increased caregiver
monitoring in completing these complex, multi-step tasks. In contrast, adherence to daily
oral medication, such as antihypertensive medicine in the current study, is a singular
behavior for which caregivers may not monitor intensely unless there is evidence that the
adolescent is not consistently taking their medicine. Differences between our findings and
those recently reported in adolescents with epilepsy (Holbein et al., 2019) may reflect that
we measured whether caregivers monitor adolescents’ antihypertensive medication regimens
(e.g., watching and asking if their child took the medicine, reminding their child to take the
medicine) rather than whether caregivers are personally responsible for managing and
administering the medications. In light of the discrepant findings about the role of caregiver
monitoring in adolescent adherence and our measure’s psychometric limitations, more
research is needed to understand how caregivers may optimally monitor adolescents’
adherence.

Author Manuscript
Author Manuscript

The current findings do not suggest that caregivers should become less involved in
adherence monitoring. Rather, they suggest that balancing caregiver monitoring,
adolescents’ growing independence, and adherence is likely challenging for adolescents with
chronic illnesses. For example, results of a pilot study of a text messaging and app-based
adherence intervention for adolescents with epilepsy showed that caregiver involvement in
the 1-month intervention did not improve adherence rates (Modi, Mann, Urso, & Peugh,
2016). This further highlights the complexity of balancing caregiver monitoring and
involvement in promoting adolescents’ medication adherence. Adolescents with CKD who
do not regularly take their antihypertensive medications may benefit from other strategies to
improve adherence. Technological advances with Bluetooth-enabled pill bottles, for
example, may allow caregivers to consistently, but unobtrusively, monitor adolescents’ real
time adherence. This approach could help caregivers intervene promptly and seek resources
from providers to improve adolescents’ adherence before it becomes an ongoing concern.
Technology-based monitoring allows for passive observation, which may help caregivers
scaffold gradually increased adolescent independence for medication management and
minimize potential caregiver-adolescent conflict. Additionally, our prior research shows that
medication self-efficacy (believing one can be adherent to a medication regimen) and
positive and negative beliefs about medications are associated over time with
antihypertensive medication adherence in adolescents with CKD (Eaton et al., 2019).
Providers may consider targeting these areas via motivational interviewing and cognitive
restructuring approaches to improve long-term adherence among typically developing
adolescents with CKD.
This study has many strengths including the use of objectively monitored medication
adherence over 24 months, adolescent and caregiver perspectives, and a proactively recruited
community-based sample. However, limitations regarding measurement, exclusion criteria,
and generalizability are worth noting. We relied on the BRIEF for measuring executive
functioning, which has low (McAuley, Chen, Goos, Schachar, & Crosbie, 2010) to moderate
(Toplak, Bucciarelli, Jain, & Tannock, 2008) relations with performance-based executive
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function assessments. Fortunately, the BRIEF has been shown to better predict disease
management compared to performance-based executive functioning assessments in other
pediatric samples (e.g., T1D; Suchy et al., 2015), suggesting that our use of the BRIEF may
have increased our predictive validity. However, our use of audio CASI in administering the
BRIEF may have reduced attentional demands normally accompanying paper-and-pencil
completion of the BRIEF and contributed to executive functioning levels observed in our
sample. Further, the BRIEF-SR and –P forms were used with eight adolescents ≥19 years at
baseline, though we found that excluding these participants resulted in a similar pattern of
effects to those observed in the full sample. Future work involving mixed methods of
performance-based and self-report measurements (including paper-and-pencil
administration) of executive function will allow for greater exploration of associations
between executive function and medication adherence in youth with CKD, while also
allowing for comparability across administration types. We also noted limitations related to
our measurement of caregiver monitoring, which was assessed with three face valid items
adapted from a measure with strong internal consistency originally validated in adolescents
with T1D (Ellis et al., 2007). Our adaptations may have contributed to the lower internal
consistency observed in our study, which led to our decision to also analyze the scale as a
cutpoint, rather than a sum score. Additionally, only caregiver report of caregiver monitoring
was obtained to reduce adolescent burden, though we acknowledge the benefit of assessing
adolescents’ perspectives of caregiver involvement. Future research is needed to validate a
caregiver monitoring scale for adolescents with CKD, both caregiver and adolescent report,
to help clarify associations between caregiver monitoring and antihypertensive medication
adherence.

Author Manuscript

Further, our recruitment strategies and exclusionary criteria may have impacted the results
and generalizability of the study. Individuals unwilling to use the MEMS cap and those with
significant developmental delay or cognitive impairment were excluded, which may have
resulted in excluding adolescents with more disease management struggles. Future
researchers may choose to expand inclusion criteria to allow for greater variability in study
samples, particularly to enhance representation of adolescents with CKD and significant
executive functioning impairments, which may increase power to detect effects. Finally,
although our participants were recruited from three pediatric nephrology clinics, these sites
were in the same geographical region and our sample was relatively small. Future
researchers may consider broadening recruitment strategies to include additional sites in
different geographic locations to increase sample sizes and statistical power and to enhance
the generalizability of findings.

Author Manuscript

Among a community-based sample of adolescents with CKD, baseline executive functioning
abilities did not appear to be associated with longitudinal, electronically-monitored
adherence to daily pill-based antihypertensive medication regimens. Caregivers may
increase their levels of monitoring because the adolescent has demonstrated nonadherence.
For healthcare providers of adolescents with CKD, there may be utility in assessing
caregiver monitoring practices to identify how much caregivers monitor adherence, whether
their level of monitoring is helping to support adherence, and what additional strategies may
be implemented to most effectively enhance adolescents’ adherence when indicated. Other
future directions include evaluating the use of technology to help caregivers unobtrusively
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monitor adolescents’ adherence and evaluating how targeting adolescents’ self-efficacy,
thoughts, and feelings about medications may provide added support of long-term
adherence.
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Figure 1.

Consort diagram of screening, recruitment, enrollment, and inclusion in final sample.
Information on reasons for adolescent ineligibility has been previously published (Eaton et
al., 2019).
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Adolescent Demographic Information
%

n

Male

57

55

Female

43

42

African American

41

40

Caucasian

42

41

Asian/Pacific Islander

4

4

Multiracial

8

8

Other

4

4

<$50,000

34

33

$50,000–99,999

30

29

≥$100,000

35

34

Not reported

1

1

Public

43

42

Private

55

53

Not reported

2

2

1

21

20

2

28

27

3

23

22

4–5

10

10

Not available during study time frame

18

18

1

74

72

2

20

19

3–4

6

6

Yes

40

39

No

60

58

Demographic variable
Gender

Race

Annual household income

Author Manuscript

Health insurance

CKD stage

Author Manuscript

Number of prescribed antihypertensive medications (baseline)

Hypertension diagnosis

Note. N = 97.
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Descriptive Data for Primary Study Variables
M(SD)

Range

n

Baseline

77.68 (23.02)

4.55 – 100

97

6 months

79.63 (25.01)

11.11 – 100

80

12 months

78.42 (28.06)

1.05 – 100

83

18 months

72.88 (29.77)

2.96 – 100

77

24 months

69.29 (27.08)

5.00 – 100

72

BRI

51.45 (10.91)

33 – 94

95

MCI

52.44 (11.19)

31 – 97

95

GEC

52.23 (11.62)

30 – 100

93

BRI

54.20 (10.32)

37 – 88

97

MCI

57.33 (10.08)

36 – 82

93

GEC

56.72 (10.39)

36 – 86

93

7.30 (2.11)

3 – 12

97

Variable
Antihypertensive Medication Adherence (% MEMS cap openings/expected openings)

Adolescent-Reported Executive Functioning (BRIEF-SR; Baseline)

Author Manuscript

Caregiver Proxy-Reported Executive Functioning (BRIEF-P; Baseline)

Caregiver Monitoring (Baseline)

Note. Higher BRIEF-SR and –P T-scores reflect more problems with executive functioning. Higher scores on Caregiver Monitoring reflect higher
levels of adherence monitoring.
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Descriptive Data for Ranges of Executive Functioning Impairments
Sub-clinical (T-score<60)

At-risk (T-score≥60)

Clinically Significant (T-score≥65)

% (n)

% (n)

% (n)

Adolescent-Reported Executive Functioning (BRIEF-SR)
BRI

82 (78)

18 (17)

8 (8)

MCI

82 (78)

18 (17)

9 (9)

GEC

78 (73)

22 (20)

11 (10)

Caregiver Proxy-Reported Executive Functioning (BRIEF-P)
BRI

73 (71)

27 (26)

18 (14)

MCI

62 (58)

38 (35)

22 (20)

GEC

66 (61)

34 (32)

24 (22)

Author Manuscript

Note. At-risk and Clinically Significant ranges are based on the recommendations from the BRIEF manual (Gioia et al., 2000; Guy et al., 2004).
Sub-clinical denotes any scores that fell below the At-risk cut-off score (T-score<60).
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.37

Time × Caregiver monitoring
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70.81
−2.77
−2.75
−6.64
4.41
1.28
10.64

Intercept

Time

Age

Gender

Race

Number of antihypertensive medications

Number of daily antihypertensive doses

Fixed effects

β

238.55

Independent variables: MCI, Caregiver monitoring

Intercept (Individual)

Variance Estimate

−.02

Random effects

−2.87

Time × BRI

.19

Caregiver monitoring

.05

BRI

End-stage renal disease status

FSIQ-2

4.94
−2.72

Transplant status

3.41

Race
1.52

−6.21

Gender

11.13

−2.70

Age

Number of daily antihypertensive doses

−2.77

Time

Number of antihypertensive medications

69.58

β

Intercept

Fixed effects

Independent variables: BRI, Caregiver monitoring

6.23

5.70

4.34

4.15

.96

.78

5.96

SE

1.71

.22

1.02

−1.60

−2.87

−3.57

11.88

t

3.56

Z

66.98

1.03

SE

−.23

−2.25

.84

.39

−.37

1.02

1.80

.27

.79

−1.50

−2.83

−3.53

11.89

t

.36

.07

1.27

.23

.14

7.44

4.86

6.17

5.65

4.31

4.13

.96

.79

5.85

SE

.09

.82

.31

.11

.004

<.001

<.001

p

<.001

p

.30

.82

.03

.40

.70

.71

.31

.07

.79

.43

.13

.005

.001

<.001

p

Adolescent Reported Executive Functioning (BRIEF-SR)

Dependent variable in all models: Antihypertensive medication adherence (time varying)

11.41

3.15

3.05

−6.45

−2.45

−2.36

68.53

β

246.06

Variance Estimate

.25

.08

−2.73

−.14

.03

−.73

4.29

11.32

1.75

4.02

−6.63

−2.70

−2.76

69.47

β

6.47

5.79

4.40

4.29

1.03

.76

6.00

SE

66.01

SE

.37

.08

1.32

.26

.14

7.13

5.02

6.33

5.76

4.32

4.25

.96

.77

5.93

SE

1.76

.54

.69

−1.50

−2.37

−3.13

11.43

t

3.73

Z

.68

1.02

−2.07

−.54

.22

−.10

.85

1.79

.30

.93

−1.56

−2.82

−3.60

11.72

t

.08

.59

.49

.13

.02

.002

<.001

p

<.001

p

.50

.31

.04

.59

.83

.92

.39

.07

.76

.35

.12

.005

<.001

<.001

p

Caregiver Proxy-Reported Executive Functioning (BRIEF-P)

Adolescent- and Caregiver Proxy-Reported Executive Functioning (Baseline) and Caregiver Monitoring (Baseline) Predicting Adherence Over Time

Author Manuscript
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−.04
.37

Caregiver monitoring

Time × MCI

Time × Caregiver monitoring

241.91

1.08
10.08
3.91
−2.71

Number of antihypertensive medications

Number of daily antihypertensive doses

Transplant status

End-stage renal disease status
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.38

Time × Caregiver monitoring

242.19

.71

Z

3.58

Z

SE
67.61

1.05

−.38

−2.16

.35

.15

−.36

.80

1.61

.19

.91

−1.38

−2.90

−3.55

11.85

t

.36

.07

1.29

.22

.14

7.49

4.92

6.26

5.74

4.40

4.19

.96

.79

5.99

SE

3.68

SE
65.82

1.03

−.52

−2.21

−.16

.02

−.09

.36

.07

1.28

.22

.14

7.16

4.87

<.001

p

.30

.70

.03

.72

.88

.72

.43

.11

.85

.36

.17

.004

.001

<.001

p

<.001

p

.30

.60

.03

.87

.98

.93

.48

2.72

260.11

Variance Estimate

.12

.04

−2.17

−.24

.05

−1.05

2.41

11.00

3.20

3.08

−6.34

−2.55

−2.37

68.81

β

256.09

Variance Estimate

.16

.01

−2.17

−.25

.04

−1.16

67.18

SE

.36

.07

1.32

.26

.14

7.22

5.16

6.54

5.86

4.43

4.37

1.03

.75

6.04

SE

66.62

SE

.36

.08

1.31

.26

.14

7.18

5.08

.53

3.87

Z

.32

.54

−1.64

−.91

.35

−.15

.47

1.68

.55

.69

−1.45

−2.48

−3.14

11.38

t

3.84

Z

.45

.14

−1.66

−.98

.31

−.16

<.001

p

.75

.59

.10

.36

.73

.88

.64

.09

.59

.49

.15

.01

.002

<.001

p

<.001

p

.65

.89

.10

.33

.76

.87

.59

Note. Higher T-scores on the BRIEF-SR and –P reflect more problems with executive functioning; higher scores on the caregiver monitoring scale reflect higher levels of caregiver adherence monitoring.

Intercept (Individual)

Variance Estimate

−.03

Time × GEC

Random effects

−2.80

Caregiver monitoring

.08

4.01

Race

GEC

−5.80

Gender

.02

−2.79

Age

FSIQ-2

71.02
−2.80

Time

β

Intercept

Fixed effects

Independent variables: GEC, Caregiver monitoring

Intercept (Individual)

Variance Estimate

−2.83

MCI

Random effects

.003
−.04

FSIQ-2

3.47
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−.63
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End-stage renal disease status

Author Manuscript

Transplant status
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